NOTA DE PRENSA DE DOCUMENTUM
mar 31, 2003 08:00 ET
AstraZeneca Deploys the Documentum ECM Platform for Web Content and Digital Asset Management
PLEASANTON, Calif., March 31 / — Documentum (NASDAQ:DCTM) , the leading provider of enterprise content management (ECM), today announced that AstraZeneca (NYSE:AZN) , a longstanding Documentum customer and one of the world’s leading pharmaceutical companies, has expanded its use of the Documentum ECM platform to include web content management and digital asset management. The Documentum products are at the foundation of the new AstraZeneca Web Content Management Service dubbed «Azgard,» which will enable the company’s sales and marketing organizations to accelerate the creation and publishing of web sites and digital assets for a growing number of Internet and intranet websites, and lower publication costs.
AstraZeneca provides innovative and effective disease-fighting medicines across a wide range of ailments. The company, which spends more than $10 million every business day in research and development, employs more than 55,000 people with sales in over 100 countries. Before standardizing on the Documentum platform, AstraZeneca managed all of its Internet and intranet sites individually, which made it difficult to easily leverage and repurpose existing content, including digital assets such as brochures, presentations, graphics and advertising copy. The Documentum solution will help AstraZeneca to reuse digital assets for substantial cost savings, lower web maintenance costs, accelerate user training and, quickly deploy new sites and ensure regulatory compliance throughout its web sites.
«Our positive experience with Documentum over the last few years led us to standardize on the Documentum platform throughout our organization,» said Steve Atkinson, Enterprise Software Manager at AstraZeneca. «Deploying Documentum’s web content management and digital asset management technologies allows us to reduce operating costs by deploying a single platform within a secure environment.»
«We are pleased that AstraZeneca has expanded its relationship with Documentum, as this reflects a growing trend among our customers who expand their use of Documentum products and standardize on the platform throughout their global organizations,» said Dave DeWalt, president and chief executive officer, Documentum. «Our market leadership is validated when global leaders such as AstraZeneca standardize on the Documentum platform as the foundation for their content management infrastructure.»
The Documentum ECM platform is deployed extensively throughout AstraZeneca, helping the company to bring new drugs to market, share best practices in the discovery of new drugs and promote product knowledge transfer through intranet applications.
Life Sciences Companies Rely On Documentum
In addition to AstraZeneca, Documentum has more than 200 customers in the pharmaceutical, biotechnology and healthcare industries, including Acurian, Aventis, Bristol-Myers Squibb, Hisamitsu Pharmaceutical Co., Schering-Plough and Hoffman-La Roche. These companies use Documentum to fulfill their challenging content management, collaboration and compliance requirements.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $17.8 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index.